Business Context and Reporting Period
Company: Mangoceuticals, Inc. (MGRX)
Filing Type: Form 8-K (Current Report)
Date of Report: January 15, 2025
Reporting Period: Events occurring on January 15, 2025.
Context: The filing details a debt-to-equity conversion, the appointment of a new President and Director, and the final closing of a Series B Preferred Stock offering.
Key Financial Metrics and Transactions
- Debt Conversion: Converted $150,000 of outstanding debt into 100,000 shares of restricted common stock at a price of $1.50 per share.
- Equity Financing: Sold 250 shares of Series B Convertible Preferred Stock for $250,000 cash (effective price $1,000/share, representing a 10% discount to the $1,100 stated value).
- Executive Compensation: New President Antonios Isaac to receive $10,000 per month plus expense reimbursement and potential discretionary equity/cash awards.
- Warrant and Conversion Adjustments: Exercise prices for outstanding warrants (covering up to 1,970,000 shares) and the conversion price for Series B Preferred Stock were automatically adjusted down to $1.50 per share.
Material Changes Versus Prior Period
This filing represents a discrete event report rather than a periodic financial statement. Material changes include:
- Capital Structure: Reduction of $150,000 in debt liabilities and issuance of 100,000 new common shares.
- Liquidity: Inflow of $250,000 from the final closing of the Series B Preferred Stock offering.
- Corporate Governance: Board size increased from 4 to 5 members with the appointment of Antonios Isaac.
- Dilution Terms: Significant downward adjustment of conversion and exercise prices for existing securities to $1.50, increasing potential future share count upon conversion/exercise.
Guidance, Outlook, and Risks
- Management Commentary: The Company cites Mr. Isaac's significant business experience and public company background as justification for his appointment.
- Unusual Items: The debt being converted was originally owed to Cohen Enterprises (owned by CEO Jacob Cohen) and was acquired by Mill End Capital Ltd. for $150,000 prior to conversion.
- Risks and Contingencies:
- Dilution Risk: The adjustment of the Series B Preferred Stock conversion price to $1.50 could result in the issuance of up to 1,848,000 common shares from existing holdings and 183,333 shares from the new closing, excluding in-kind dividends.
- Related Party Transactions: The debt conversion involves a note originally held by the CEO's entity.
- Transfer Restrictions: All newly issued securities (Debt Conversion Shares and Series B Preferred Stock) are unregistered and subject to transfer restrictions under Section 4(a)(2) and Rule 506 of Regulation D.
Investor Verification Checklist
- Verify the exact number of outstanding Series B Preferred Stock shares and the total potential common share dilution upon full conversion at the new $1.50 floor price.
- Confirm the total number of outstanding warrants and the aggregate number of shares issuable upon exercise at the adjusted $1.50 price.
- Review the full text of the Debt Conversion Agreement (Exhibit 10.1) to understand any covenants or restrictions on the 100,000 shares issued to Mill End Capital.
- Assess the impact of the $120,000 annual cash compensation for the new President on the Company's current cash burn rate.
- Confirm the status of the remaining 2,520 shares of Series B Preferred Stock and their conversion terms.